Xiao-lan Jin

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
AIM Oral risedronate is effective in the treatment of postmenopausal osteoporosis when administered daily, weekly, or monthly. In this 1-year, randomized, double-blind, multicenter study we compared the weekly 35-mg and daily 5-mg risedronate dosing regimens in the treatment of Chinese postmenopausal women with osteoporosis or osteopenia. METHODS(More)
  • 1